| EMA number | EMEA/H/C/000307 |
| ATC code | B01AD |
| Authorisation | 23 February 2001 |
| Withdrawn | 9 August 2005 |
| Revision | 2 |
Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.
TNKASE — GENENTECH, approved 2025-02-28 (BLA103909).
1,623 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.